相关实验视频
Updated: Sep 10, 2025
11:12
Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
Published on: July 16, 2014
22.6K
在帕金森病中寻找疾病修饰 - - 文献综述
Daniel Barber1,2,3,4, Tissa Wijeratne1,3,4,5,6, Lakshman Singh1,3,4,5,7
1Department of Neurology, Sunshine Hospital, Western Health, St Albans, VIC 3021, Australia.
Life (Basel, Switzerland)
|August 28, 2025
概括
帕金森病 (PD) 涉及加速的神经退行,特别是在黑色物质 (SNpc) 中. 研究正在探索α-synuclein,氧化应激和炎症,以寻找疾病修饰疗法.
科学领域:
- 神经科学
- 老年学
- 病理学
背景情况:
- 帕金森病 (PD) 是一个日益严重的全球健康问题,
- 在老年大脑中常见的神经退行,在PD的特定区域加速,特别是黑色质体 (SNpc).
- 细胞功能,生物能衰竭和免疫反应的复杂相互作用是PD加速神经退行的基础.
研究的目的:
- 审查有关帕金森病神经退行现有证据.
- 专注于阿尔法同核素,氧化应激和PD进展中的炎症.
- 讨论和评估最近的疾病修饰治疗方法.
主要方法:
- 关于帕金森病神经退行现有科学文献的综述.
- 对聚焦于α-synuclein,氧化应激和神经炎症的研究分析.
- 检查新兴的治疗策略,包括干细胞治疗和生长因子.
主要成果:
- 阿尔法同核素的积累和沉积是PD的关键病理特征.
- 氧化应激和慢性炎症显著导致神经退行.
- 新兴疗法旨在针对这些途径,包括α-synuclein,氧化应激和免疫反应.
结论:
- 了解神经退行症的复杂机制对于开发有效治疗至关重要.
- 针对α-synuclein,氧化应激和神经炎症提供了疾病修饰的有希望的途径.
- 未来的研究必须解决方法上的局限性,例如早期的患者招募,以推进治疗的发展.
相关概念视频
01:24Parkinson's Disease: Treatment
376
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
376
01:15Parkinson's Disease: Overview
702
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
702
01:37Neural Regulation
39.9K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.9K
01:22Alzheimer's Disease: Treatment
260
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
260
01:28Drug Therapy
96
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
96
01:22Lysosomal Hydrolases
3.9K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.9K